Table 4. Multivariate COX regression analysis of the association of Ano1 and Ki67 expression with DFS and OS in breast cancer patients.
| Variable | DFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| Total n. |
Events n (%) |
Adjusted HR (95%CI) |
P value† | Total n |
Events n (%) |
Adjusted HR (95%CI) |
P value† | |
| Ano1 Expression | ||||||||
| ER-positive patients | ||||||||
| Low | 117 | 7 (6.0) | 1 (reference) | 117 | 16 (13.7) | 1 (reference) | ||
| High | 161 | 19 (11.8) | 1.869(0.780-4.480) | 0.161 | 161 | 12 (7.5) | 0.503(0.236-1.070) | 0.074 |
| ER-negative patients | ||||||||
| Low | 58 | 6 (10.3) | 1 (reference) | 58 | 10 (17.2) | 1 (reference) | ||
| High | 71 | 5 (7.0) | 0.561(0.164-1.913) | 0.356 | 71 | 11 (15.5) | 0.938(0.391-2.252) | 0.887 |
| PR-positive patients | ||||||||
| Low | 111 | 10 (9.0) | 1 (reference) | 111 | 16 (14.4) | 1 (reference) | ||
| High | 164 | 16 (9.8) | 1.015(0.455-2.262) | 0.971 | 164 | 11 (6.7) | 0.425(0.196-0.921) | 0.030 |
| PR-negative patients | ||||||||
| Low | 64 | 3 (4.7) | 1 (reference) | 64 | 10 (15.6) | 1 (reference) | ||
| High | 68 | 8 (11.8) | 2.065(0.536-7.961) | 0.292 | 68 | 12 (17.6) | 1.087(0.465-2.540) | 0.848 |
| HER2-positive patients | ||||||||
| Low | 29 | 3 (10.3) | 1 (reference) | 29 | 5(17.2) | 1 (reference) | ||
| High | 67 | 8 (11.9) | 0.955(0.240-3.805) | 0.948 | 67 | 13(19.4) | 1.498(0.489-4.589) | 0.479 |
| HER2-negative patients | ||||||||
| Low | 285 | 149 (52.3) | 1 (reference) | 280 | 155(55.4) | 1 (reference) | ||
| High | 26 | 16 (61.5) | 1.256(0.564-2.794) | 0.577 | 31 | 10(32.3) | 0.388(0.182-0.826) | 0.014 |
| Patients with the low expression of Ki67 | ||||||||
| Low | 106 | 8(7.5) | 1 (reference) | 106 | 14(13.2) | 1 (reference) | ||
| High | 169 | 19(11.2) | 1.226(0.585-2.570) | 0.590 | 169 | 9(5.3) | 0.536(0.282-1.019) | 0.057 |
| Patients with the high expression of Ki67 | ||||||||
| Low | 22 | 2(9.1) | 1 (reference) | 22 | 4(18.2) | 1 (reference) | ||
| High | 19 | 2(10.5) | 2.146(0.334-13.785) | 0.421 | 19 | 5(26.3) | 1.569(0.445-5.526) | 0.483 |
| Lymph node-negativepatients | ||||||||
| Low | 79 | 11(13.9) | 1 (reference) | 79 | 5(6.3) | 1 (reference) | ||
| High | 120 | 14(11.7) | 0.783(0.351-1.750) | 0.551 | 120 | 5(4.2) | 0.533(0.151-1.877) | 0.327 |
| Lymph node-positivepatients | ||||||||
| Low | 96 | 23(24.0) | 1 (reference) | 96 | 21(21.9) | 1 (reference) | ||
| High | 112 | 26(23.2) | 0.975(0.546-1.678) | 0.879 | 112 | 18(16.1) | 0.694(0.370-1.303) | 0.256 |
| ER-negativepatients with the low expression of Ki67 | ||||||||
| Low | 48 | 11(22.9) | 1 (reference) | 48 | 8(16.7) | 1 (reference) | ||
| High | 62 | 12(19.4) | 0.870(0.376-2.015) | 0.746 | 62 | 9(14.5) | 0.900(0.340-2.385) | 0.832 |
| ER-positive patients with the low expression of Ki67 | ||||||||
| Low | 97 | 17(17.5) | 1 (reference) | 97 | 13(13.4) | 1 (reference) | ||
| High | 146 | 21(14.4) | 0.722(0.407-1.468) | 0.431 | 146 | 8(5.5) | 0.374(0.155-0.906) | 0.029 |
| PR-negative patients with the low expression of Ki67 | ||||||||
| Low | 51 | 11(21.6) | 1 (reference) | 51 | 9(17.6) | 1 (reference) | ||
| High | 62 | 15(24.2) | 1.082(0.492-2.379) | 0.844 | 62 | 10(16.1) | 0.880(0.353-2.194) | 0.880 |
| PR-positive patients with the low expression of Ki67 | ||||||||
| Low | 94 | 17(18.1) | 1 (reference) | 94 | 12(12.8) | 1 (reference) | ||
| High | 146 | 18(12.3) | 0.627(0.320-1.227) | 0.173 | 146 | 7(4.8) | 0.328(0.128-0.841) | 0.020 |
| HER2-negative patients with the low expression of Ki67 | ||||||||
| Low | 120 | 22(18.3) | 1 (reference) | 120 | 17(14.2) | 1 (reference) | ||
| High | 149 | 17(12.1) | 0.602(0.321-1.127) | 0.113 | 149 | 7(4.7) | 0.296(0.122-0.717) | 0.007 |
| HER2-positive patients with the low expression of Ki67 | ||||||||
| Low | 25 | 6(24.0) | 1 (reference) | 25 | 4(16.0) | 1 (reference) | ||
| High | 59 | 15(25.4) | 1.212(0.456-3.225) | 0.700 | 59 | 10(16.9) | 1.402(0.420-4.680) | 0.583 |
| Ki67 Expression | ||||||||
| Lymph node-negative patients | ||||||||
| Low | 177 | 23(13.0) | 1 (reference) | 177 | 9(5.1) | 1 (reference) | ||
| High | 22 | 2(9.1) | 0.667(0.155-2.861) | 0.585 | 22 | 1(4.1) | 0.831(0.104-6.641) | 0.861 |
| Lymph node-positive patients | ||||||||
| Low | 176 | 38(21.6) | 1 (reference) | 176 | 29(16.5) | 1 (reference) | ||
| High | 32 | 11(34.4) | 0.551(0.280-1.087) | 0.085 | 32 | 10(31.3) | 0.482(0.233-0.995) | 0.048 |
| Lymph node-positive patients with the high expression of Ano1 | ||||||||
| Low | 98 | 20(20.4) | 1 (reference) | 98 | 13(13.3) | 1 (reference) | ||
| High | 14 | 6(42.9) | 2.649(1.060-6.617) | 0.037 | 14 | 5(35.7) | 3.286(1.170-9.228) | 0.024 |
| Lymph node-positive patients with the low expression of Ano1 | ||||||||
| Low | 78 | 18(23.1) | 1 (reference) | 78 | 16(20.5) | 1 (reference) | ||
| High | 18 | 5(27.8) | 1.262(0.468-3.400) | 0.646 | 18 | 5(27.8) | 1.453(0.532-3.970) | 0.466 |
Abbreviations: HR: Hazard Ratio; 95% CI, 95% confidence interval; DFS: Disease-free survival; OS: Overall survival; Ref, reference category; ER, Estrogen receptor; PR, Progesterone receptor; HER2, Human epidermal growth factor receptor.
†P values, Adjusted HR(95%CI) were assessed using multivariate Cox regression analysis adjusted for age and menopausal status.